Please assess the completion status of the following clinical trial:

Trial Title: Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 3-12 years of age~* Suffering from a mild to moderate atopic dermatitis that is amenable to treatment with moisturizer only~* SCORAD (scoring atopic dermatitis) of 10-30 at screening and Day 0~* Diagnosis of atopic dermatitis must meet Hanifin's criteria (at least 3 basic features and at least 3 minor features; please refer to appendix D)~* Atopic dermatitis has been, in the opinion of the investigator, stable for the past 28 days~* Subject with parents able to apply the study product twice a day (each morning and evening) for a 56 days period~* Subject with parents agreeing not to change their child's lifestyle during the study period (including their usual body hygiene product (soap), the number of baths and showers per day, the laundry detergent and fabric softener used to wash the child's clothes)~* Subject with parents agreeing that their child uses only the test product as body emollient on the whole body during the study period~* Subject with parents available to completely follow the study with their child~* Subject with parents able and willing to sign the informed consent form and to comply with the study regulations of this protocol~Exclusion Criteria:~* Subject has another dermatological condition that could interfere with clinical evaluation including infected atopic dermatitis lesions~* Subject has a previous history of allergy to cosmetic products or any ingredients of the tested formulations~* Subject has received any systemic treatment, including PUVA (psoralen ultraviolet A) therapy for atopic dermatitis within 28 days prior to screening~* Subject has received any topical immunomodulators for atopic dermatitis (such as pimecrolimus or tacrolimus) within 14 days of Day 0~* Subject has received phototherapy within 14 days of Day 0~* Subject intends to expose him/herself to the sun during the trial~* Subject has known allergy to any component of tested products~* Subject has used any experimental treatment within 14 days of Day 0~* Subject has used any topical corticosteroid of class I-IV within 14 days of Day 0

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Formulation 609580 20 then 609209 (Type: EXPERIMENTAL): Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
- Formulation 609209 then 609580 20 (Type: ACTIVE_COMPARATOR): Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility